EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)KohortenstudieOpen Access · CC BY-NC 4.0

Anti‐PD‐L1 antibody TQB2450 combined with tyrosine kinase receptor inhibitor AL2846 for immunotherapy‐refractory advanced hepatocellular carcinoma and esophageal squamous cell carcinoma: A prospective phase 1b cohort study

Tao Ning, Danyang Li, Ting Deng, Yuxian Bai, Ye Chen, Zhiyu Wang, Bin Hu, Yi Ba iD, Wei Lu

Cancer · 2024

DOI: 10.1002/cncr.35377 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Cancer, 2024. Verfasst von Tao Ning und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Medical Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Canc…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Esophageal Squamous Cell Carcinoma, Liver Neoplasms, Esophageal Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Tianjin Key Medical Discipline (Specialty) Construction Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Effective systemic therapy remains limited for advanced esophageal squamous cell carcinoma (ESCC) and hepatocellular carcinoma (HCC), particularly after prior failed treatment with immune checkpoint inhibitors (ICIs). Theoretically, a combination of tyrosine kinase inhibitors (TKIs) with ICIs may restore immunotherapy sensitivity.

Methods

In this phase 1b study, patients received AL2846, an antiangiogenic TKI with multiple targets (c‐MET, VEGFR1, c‐KIT, Axl, RET, KDR, and VEGFR3), in combination with an anti–PD‐L1 antibody (TQB2450) until disease progression, intolerable toxicity, death, or discontinuation for any cause. The primary end points included overall response rate (ORR) and safety, with secondary end points encompassing progression‐free survival (PFS), overall survival (OS), disease control rate (DCR), and duration of response.

Results

Between November 2021 and September 2022, 18 patients with ESCC and 15 patients with HCC, whose ORR was 11.1% (95% confidence interval [CI], 3.1%–32.8%) and 0%, respectively, were enrolled. Adverse events (AEs) of any grade and treatment‐related AEs were documented in 32 patients (97.0%) and 31 patients (93.9%), respectively. Grade 3 or higher AEs were observed in 10 patients (30.3%), with vomiting (6.1%) and infectious pneumonia (9.1%) being the most prevalent. Median PFS and OS values were 3.22 months (95% CI, 1.35–5.68 months) and 5.98 months (95% CI, 3.71–8.87 months), respectively, in patients with ESCC, and 5.55 months (95% CI, 2.66 months to not evaluable [NE]) and 16.72 months (95% CI, 4.86 months to NE), respectively, in patients with HCC. The DCRs were 66.7% (95% CI, 43.75%–83.72%) in patients with ESCC and 73.3% (95% CI, 48.05%–89.10%) in patients with HCC.

Conclusions

Combined TQB2450 and AL2846 therapy exhibited a favorable safety profile in immunotherapy‐refractory patients with advanced ESCC and HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularEsophageal Squamous Cell CarcinomaLiver NeoplasmsEsophageal NeoplasmsHumansMaleFemaleMiddle AgedAgedProspective StudiesProtein Kinase InhibitorsImmune Checkpoint InhibitorsB7-H1 AntigenAntineoplastic Combined Chemotherapy ProtocolsAdultImmunotherapyDrug Resistance, NeoplasmAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

AL2846TQB2450esophageal squamous cell carcinomahepatocellular carcinomaimmunotherapy‐refractory

Substanzen

Protein Kinase InhibitorsImmune Checkpoint InhibitorsB7-H1 AntigenCD274 protein, humanAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Gastrointestinal Medical Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin Key Laborat…
  • Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
  • Department of Oncology Surgery, Henan Key Laboratory of Cancer Epigenetics, Cancer Hospital, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Lu…
  • Department of Immuno-Oncology, Affiliated Hospital of Hebei University, Shijiazhuang, China.
  • Department of biostatistics and SAS programming, Chai Tai Tianqing Pharmaceutical Group Co, Ltd, Nanjing, China.
  • Department of Cancer Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.

ORCID-Profile: Yi Ba

Förderung

  • Tianjin Key Medical Discipline (Specialty) Construction Project

Zitieren

APA

Ning, T., Li, D., Deng, T., Bai, Y., Chen, Y., Wang, Z., Hu, B., Ba, Y., & Lu, W. (2024). Anti‐PD‐L1 antibody TQB2450 combined with tyrosine kinase receptor inhibitor AL2846 for immunotherapy‐refractory advanced hepatocellular carcinoma and esophageal squamous cell carcinoma: A prospective phase 1b cohort study. Cancer. https://doi.org/10.1002/cncr.35377

Vancouver

Ning T, Li D, Deng T, Bai Y, Chen Y, Wang Z, et al. Anti‐PD‐L1 antibody TQB2450 combined with tyrosine kinase receptor inhibitor AL2846 for immunotherapy‐refractory advanced hepatocellular carcinoma and esophageal squamous cell carcinoma: A prospective phase 1b cohort study. Cancer. 2024. doi:10.1002/cncr.35377

BibTeX
@article{Ning2024,
  author = {Ning, Tao and Li, Danyang and Deng, Ting and Bai, Yuxian and Chen, Ye and Wang, Zhiyu and Hu, Bin and Ba, Yi and Lu, Wei},
  title = {Anti‐PD‐L1 antibody TQB2450 combined with tyrosine kinase receptor inhibitor AL2846 for immunotherapy‐refractory advanced hepatocellular carcinoma and esophageal squamous cell carcinoma: A prospective phase 1b cohort study},
  journal = {Cancer},
  year = {2024},
  doi = {10.1002/cncr.35377}
}
Kostenlos starten →